Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Migraine
← New Search

Migraine

Educational clinical summary of Migraine for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Medical Disclaimer: This document provides comprehensive medical information for educational purposes and as a clinical reference. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always use their independent medical judgment in the context of individual patient circumstances, considering all available clinical data and current best practices. Information contained herein should not be used to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Medical knowledge is constantly evolving; always refer to the latest guidelines and evidence.

Overview

  • Definition: Migraine is a primary headache disorder characterized by recurrent headache attacks that are typically unilateral, throbbing, moderate to severe in intensity, and aggravated by physical activity. These attacks are often associated with nausea, vomiting, photophobia (increased sensitivity to light), and phonophobia (increased sensitivity to sound).

    • ICHD-3 Criteria for Migraine without Aura:
      • A. At least 5 attacks fulfilling criteria B–D.
      • B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated).
      • C. Headache has at least two of the following four characteristics:
        1. Unilateral location
        2. Pulsating quality
        3. Moderate or severe pain intensity
        4. Aggravation by or causing avoidance of routine physical activity (e.g., walking, climbing stairs)
      • D. During headache, at least one of the following:
        1. Nausea and/or vomiting
        2. Photophobia and phonophobia
      • E. Not better accounted for by another ICHD-3 diagnosis.
    • ICHD-3 Criteria for Migraine with Aura:
      • A. At least 2 attacks fulfilling criteria B and C.
      • B. One or more of the following fully reversible aura symptoms:
        1. Visual
        2. Sensory
        3. Speech and/or language
        4. Motor
        5. Brainstem
        6. Retinal
      • C. At least two of the following four characteristics:
        1. At least one aura symptom spreads gradually over ≥5 minutes, and/or two or more symptoms occur in succession.
        2. Each individual aura symptom lasts 5-60 minutes.
        3. At least one aura symptom is unilateral.
        4. The aura is accompanied or followed within 60 minutes by headache.
      • D. Not better accounted for by another ICHD-3 diagnosis.

  • Epidemiology:

    • Prevalence: Highly prevalent, affecting approximately 12-15% of the general population worldwide.
    • Gender: About 2-3 times more common in women than men, especially during reproductive years (from puberty to menopause).
    • Age: Onset typically occurs in adolescence or early adulthood, with peak prevalence in individuals 25-55 years old. Childhood migraine exists, often presenting differently (e.g., bilateral pain, shorter duration). Prevalence tends to decrease after age 50.
    • Impact: Ranked as the second leading cause of disability worldwide and the leading cause of disability among young adults.

  • Classification:

    • Migraine without Aura (Common Migraine): The most prevalent subtype, accounting for 70-80% of cases.
    • Migraine with Aura (Classic Migraine): Characterized by transient focal neurological symptoms (aura) that usually precede or sometimes accompany the headache.
      • Typical Aura with Headache: Most common.
      • Typical Aura without Headache: "Acephalgic migraine" or "silent migraine"; aura symptoms occur without subsequent headache. More common in older adults.
      • Migraine with Brainstem Aura: Formerly Basilar-type migraine; involves at least two reversible aura symptoms originating from the brainstem (e.g., vertigo, dysarthria, diplopia, tinnitus, hypacusis, ataxia, altered consciousness).
      • Hemiplegic Migraine: Rare; involves motor weakness as an aura symptom. Can be familial (FHM, caused by mutations in CACNA1A, ATP1A2, SCN1A genes) or sporadic.
      • Retinal Migraine: Very rare; characterized by monocular visual disturbances (scintillations, scotoma, blindness) accompanied or followed by headache.
    • Chronic Migraine: Headaches occurring on 15 or more days per month for more than 3 months, with at least 8 days per month meeting criteria for migraine without aura or migraine with aura. Often associated with medication overuse headache.
    • Complications of Migraine:
      • Status Migrainosus: A debilitating migraine attack lasting >72 hours despite treatment.
      • Persistent Aura without Infarction: Aura symptoms lasting longer than one week without evidence of infarction on imaging.
      • Migrainous Infarction: Ischemic stroke occurring during a typical migraine with aura attack, where symptoms are not fully reversible and imaging confirms infarction.
    • Probable Migraine: Meets most but not all criteria for migraine with or without aura.

Pathophysiology

  • Mechanism: Migraine is a complex neurobiological disorder involving the trigeminal neurovascular system, brainstem nuclei, and cortical structures. The exact mechanism is not fully understood but involves:

    • Cortical Spreading Depression (CSD): A wave of neuronal and glial depolarization that slowly spreads across the cerebral cortex, particularly implicated in migraine with aura. CSD can activate the trigeminal afferents and lead to the release of inflammatory mediators.
    • Trigeminovascular System Activation: Activation of the trigeminal nerve, specifically its afferent fibers innervating the meningeal blood vessels, is central. This leads to the release of vasoactive neuropeptides, most notably Calcitonin Gene-Related Peptide (CGRP), substance P, and neurokinin A, causing neurogenic inflammation and sensitization of perivascular nociceptors.
    • Brainstem Involvement: Functional imaging studies show activation of brainstem nuclei (e.g., dorsal raphe nucleus, locus coeruleus, periaqueductal gray) during migraine attacks. These areas modulate pain pathways and are involved in sensory processing.
    • Hypothalamic Activation: The hypothalamus may play a role in the premonitory phase (prodrome) of migraine, regulating sleep, appetite, and mood changes.
    • Sensitization:
      • Peripheral Sensitization: Occurs early in the attack, involving nociceptors in the meninges, leading to throbbing pain.
      • Central Sensitization: Sustained input from the trigeminal system leads to increased excitability of neurons in the trigeminal nucleus caudalis and higher brain centers, contributing to allodynia (pain from non-painful stimuli) and persistent pain.

  • Risk Factors:

    • Genetic Predisposition: Strong genetic component, especially for migraine with aura and hemiplegic migraine. Family history is a major risk factor.
    • Gender: Female sex (due to hormonal fluctuations, especially estrogen).
    • Hormonal Changes: Menstruation, ovulation, puberty, pregnancy, menopause, and oral contraceptive use can trigger or modify migraine.
    • Stress: Physical or emotional stress is a common trigger.
    • Sleep Disturbances: Insomnia, oversleeping, irregular sleep patterns.
    • Dietary Factors: Certain foods (aged cheese, processed meats, chocolate, citrus fruits, nuts), food additives (MSG, artificial sweeteners like aspartame), alcohol (especially red wine), caffeine withdrawal. (Note: These are highly individual and not universal triggers.)
    • Environmental Factors: Weather changes (barometric pressure changes), strong odors (perfumes, chemicals), bright or flickering lights, loud noises.
    • Physical Factors: Dehydration, hunger, intense physical exertion, head trauma.
    • Medication Overuse: Regular overuse of acute headache medications (analgesics, triptans) can lead to medication overuse headache (MOH), which can worsen migraine frequency and severity, transitioning episodic migraine into chronic migraine.
    • Comorbidities: Psychiatric disorders (depression, anxiety), other chronic pain conditions, obesity, stroke, epilepsy.

  • Protective Factors:

    • Regular Lifestyle: Consistent sleep schedule, regular meals, adequate hydration.
    • Stress Management: Relaxation techniques, mindfulness, biofeedback, cognitive behavioral therapy (CBT).
    • Regular Exercise: Moderate, consistent physical activity (avoiding overexertion for those with exertional triggers).
    • Trigger Identification and Avoidance: Keeping a headache diary to identify and then avoid personal triggers.
    • Hormonal Regulation: For some women, consistent estrogen levels (e.g., continuous combined oral contraceptives for menstrual migraine) might be helpful, but this needs careful consideration due to stroke risk in migraine with aura.
    • Pharmacological Prevention: Appropriate use of prophylactic medications for frequent or disabling attacks.

Clinical Presentation

Signs and Symptoms

Migraine attacks typically evolve through distinct phases, though not all phases occur in every patient or every attack.

  • Cardinal Features (Headache Phase):

    • Pain Quality: Pulsating, throbbing, pounding.
    • Intensity: Moderate to severe (interferes with daily activities).
    • Location: Typically unilateral (60-70% of cases), but can be bilateral, frontal, temporal, or occipital.
    • Aggravation: Worsened by routine physical activity (e.g., walking, bending over).
    • Associated Symptoms:
      • Nausea (80%) and/or vomiting (50%).
      • Photophobia (light sensitivity) – seeking dark rooms.
      • Phonophobia (sound sensitivity) – seeking quiet environments.
      • Osmophobia (smell sensitivity) in some cases.
      • Allodynia (pain from non-painful stimuli like touch or brushing hair) in some patients.

  • Early Signs (Prodrome/Premonitory Phase): Occurs hours to days before the headache in about 60% of patients.

    • Neurological: Yawning, difficulty concentrating, phonophobia, photophobia, hyperosmia (heightened sense of smell), difficulty with language.
    • Psychological: Mood changes (depression, irritability, euphoria), anxiety.
    • Autonomic: Neck stiffness, fatigue, yawning, polyuria, diarrhea, fluid retention, food cravings.

  • Advanced Signs (Aura Phase): Occurs in 20-30% of migraineurs, usually before the headache, lasting 5-60 minutes. Fully reversible.

    • Visual Aura (most common):
      • Scintillating scotoma (zigzag lines, fortifications, shimmering lights, often arc-shaped, slowly expanding).
      • Loss of vision (hemianopsia or quadrantinopsia).
      • Flashes of light.
    • Sensory Aura: Numbness, tingling (paresthesias) spreading slowly over a body part (e.g., fingers, arm, face).
    • Speech/Language Aura: Dysphasia, difficulty finding words.
    • Motor Aura (Hemiplegic Migraine): Unilateral weakness (rare).
    • Brainstem Aura: Vertigo, diplopia, tinnitus, hypacusis, ataxia, dysarthria, altered consciousness.

  • Late-stage Presentations (Postdrome Phase): Follows the headache phase, lasting hours to a day.

    • Fatigue, exhaustion, malaise.
    • "Migraine hangover": Cognitive difficulties, difficulty concentrating, neck stiffness, muscle tenderness, mood changes (e.g., feeling drained or irritable).
    • Scalp tenderness.

  • Atypical Presentations:

    • Migraine with typical aura without headache (Acephalgic Migraine): Aura symptoms occur without a subsequent headache. More common in older individuals.
    • Status Migrainosus: Severe migraine attack lasting more than 72 hours, unresponsive to usual acute treatments. Often requires emergency care.
    • Migrainous Infarction: Rarely, migraine with aura can be associated with an ischemic stroke.
    • Persistent Aura without Infarction: Aura symptoms persist for more than one week, even after the headache resolves, and without evidence of infarction on neuroimaging.
    • Chronic Migraine: Headaches (migraine-like) on ≥15 days/month for >3 months, with at least 8 of these meeting migraine criteria.

Physical Examination

The physical examination in migraine is typically normal, but it is crucial for ruling out secondary causes of headache.

  • Inspection:
    • General Appearance: Patients may appear fatigued, pale, or in distress during an attack.
    • Head/Face: No specific external findings.
  • Palpation:
    • Scalp and Neck: May reveal tenderness, especially during the postdrome phase or with concurrent tension-type headache. Palpation over temporal arteries (to rule out giant cell arteritis in older patients).
    • Sinuses: Palpation over frontal and maxillary sinuses to rule out sinusitis.
  • Special Tests:
    • Neurological Examination:
      • Cranial Nerves: Assess pupillary light reflexes (photophobia), extraocular movements, visual fields (visual aura). Fundoscopic exam for papilledema (suggests increased intracranial pressure).
      • Motor, Sensory, Reflexes: Should be normal. Any focal neurological deficit (e.g., weakness, altered sensation, asymmetric reflexes) would raise suspicion for a secondary headache cause (e.g., stroke, tumor) and warrant further investigation, especially if not consistent with typical migraine aura.
      • Cerebellar: Assess coordination, gait, balance.
      • Mental Status: Typically normal between attacks; may show mild cognitive slowing or irritability during an attack or postdrome.
    • Meningeal Signs: Neck stiffness (nuchal rigidity), Brudzinski's sign, Kernig's sign should be absent. Presence of these signs suggests meningitis or subarachnoid hemorrhage and requires urgent investigation.

Diagnostic Approach

The diagnosis of migraine is primarily clinical, based on a detailed history. Laboratory tests and imaging are generally not required for typical migraine presentations but are essential to exclude secondary causes when red flags are present.

History Taking

  • Key Questions:

    • Headache Characteristics (PQRST):
      • Provoking/Palliating factors: What triggers it? What makes it better/worse?
      • Quality: Pulsating, throbbing, dull, pressure?
      • Radiation/Region: Unilateral, bilateral, frontal, temporal, occipital? Does it spread?
      • Severity: On a scale of 0-10. Does it interfere with daily activities?
      • Timing: Onset (sudden vs. gradual), duration (4-72 hours?), frequency (per month/week).
    • Associated Symptoms: Nausea, vomiting, photophobia, phonophobia, osmophobia, aura symptoms (describe in detail: type, duration, progression), allodynia.
    • Prodromal and Postdromal Symptoms: Yawning, mood changes, neck stiffness before; fatigue, brain fog after.
    • Triggers: Specific foods, stress, sleep patterns, hormonal changes (menstrual cycle), weather, odors.
    • Family History: Is there a family history of migraine?
    • Response to Medications: What acute and preventive medications have been tried? Were they effective? Any side effects?
    • Impact on Daily Life: How does migraine affect work, school, social activities, quality of life?
    • Medication Use: Frequency and type of acute pain medications used (to assess for medication overuse headache).

  • Red Flags (SNOOP10): These are warning signs that suggest a secondary, potentially life-threatening cause of headache and warrant further investigation.

    • Systemic symptoms: Fever, weight loss, cancer, HIV, pregnancy.
    • Neurologic symptoms/signs: Focal neurological deficit (e.g., weakness, numbness, diplopia), papilledema, seizures, altered mental status (not typical for migraine aura).
    • Onset: Sudden, thunderclap headache (peaking within 1 minute).
    • Older age: New onset headache after age 50 (e.g., temporal arteritis, tumor).
    • Pattern change: First or worst headache ever, change in usual headache pattern (frequency, severity, character).
    • Positional headache: Worsened by standing (low CSF pressure) or lying flat (high CSF pressure).
    • Precipitated by Valsalva: Cough, strain, sneeze (suggests increased intracranial pressure or structural lesion).
    • Papilledema: Swelling of the optic disc (suggests increased intracranial pressure).
    • Progressive headache: Increasing in severity or frequency over weeks or months.
    • Post-traumatic: Headache following head injury.
    • Painkiller overuse: Suspect medication overuse headache if acute medications used frequently (e.g., ≥10-15 days/month).

Laboratory Tests

  • First-Line:

    • Generally not indicated for the diagnosis of typical migraine.
    • When Red Flags are Present:
      • Complete Blood Count (CBC): To check for infection, anemia.
      • Erythrocyte Sedimentation Rate (ESR) and C-reactive Protein (CRP): Essential for ruling out giant cell arteritis in patients over 50 with new-onset headache, jaw claudication, visual changes, or scalp tenderness.
      • Thyroid Stimulating Hormone (TSH): Hypothyroidism can be associated with headache.
      • Electrolytes, Renal/Liver Function Tests: If underlying systemic illness is suspected or before starting certain medications.
      • Toxicology Screen: If substance abuse is suspected.
      • Lumbar Puncture (LP): If meningitis, encephalitis, subarachnoid hemorrhage (with negative CT), or idiopathic intracranial hypertension (IIH) is suspected. Analyze CSF for cell count, protein, glucose, culture, and opening pressure.

  • Confirmatory: No specific laboratory test confirms migraine.

  • Monitoring:

    • Liver/Renal Function Tests: For patients on long-term preventive medications (e.g., valproate, topiramate) to monitor for adverse effects.
    • CBC: For patients on topiramate (rarely causes hematologic abnormalities).
    • Electrolytes: For patients on topiramate (risk of metabolic acidosis).

Imaging

  • Recommended (When to Image): Neuroimaging (CT or MRI) is not routinely recommended for patients with a clear history of migraine without any red flags or atypical features. Imaging is indicated to rule out secondary causes of headache in the presence of:

    • Red Flags: As listed above (e.g., thunderclap headache, focal neurological deficit, new-onset headache in older patients, papilledema, pattern change).
    • Atypical Aura: Aura that is prolonged (>60 minutes), purely motor (e.g., hemiplegic migraine where secondary causes must be ruled out), or accompanied by atypical features.
    • Status Migrainosus: To rule out secondary causes of prolonged severe headache.
    • First or Worst Headache: Always warrants imaging.
    • Unexplained Seizures: Especially if associated with headache.
    • Change in Headache Pattern: For a previously stable migraine.

  • Advanced (Type of Imaging):

    • MRI Brain (with and without contrast): Preferred imaging modality for evaluating headache due to its superior soft tissue resolution, allowing better visualization of brain tumors, structural lesions, demyelinating disease, vascular malformations, and subtle pathology. It can detect migrainous infarction.
    • CT Head (without contrast): More readily available and quicker, good for detecting acute hemorrhage (subarachnoid, intraparenchymal), hydrocephalus, or large mass lesions. Often used in emergency settings for acute onset severe headache.
    • MR Angiography (MRA) or CT Angiography (CTA): May be considered if vascular abnormalities (e.g., aneurysm, dissection, vasculitis) are suspected.
    • MR Venography (MRV): If cerebral venous thrombosis is suspected.

Management

Management of migraine involves two main strategies: acute treatment (for ongoing attacks) and preventive treatment (to reduce frequency and severity).

Acute Management

Aims to treat the headache and associated symptoms quickly, effectively, and with minimal side effects. Should be taken at the first sign of an attack.

  • Immediate (First-hour Interventions):

    • Simple Analgesics/NSAIDs: For mild to moderate attacks.
      • Ibuprofen: 400-800 mg PO.
      • Naproxen: 500-1000 mg PO.
      • Aspirin: 900-1000 mg PO (often combined with caffeine and acetaminophen).
      • Diclofenac potassium: 50 mg PO.
    • Triptans (Serotonin 5-HT1B/1D Receptor Agonists): First-line for moderate to severe attacks, or mild attacks that are disabling. Should be taken early in the headache phase (not during aura).
      • Sumatriptan: PO 25-100 mg; SC 4-6 mg; Nasal spray 5-20 mg.
      • Zolmitriptan: PO 2.5-5 mg; Nasal spray 5 mg.
      • Rizatriptan: PO 5-10 mg.
      • Naratriptan: PO 1-2.5 mg (slower onset, longer duration, fewer side effects).
      • Eletriptan: PO 20-40 mg.
      • Frovatriptan: PO 2.5 mg (slowest onset, longest duration, useful for menstrual migraine).
      • Contraindications: Ischemic heart disease, uncontrolled hypertension, history of stroke/TIA, peripheral vascular disease, Wolff-Parkinson-White syndrome, severe hepatic impairment, concurrent use of MAO inhibitors (within 2 weeks) or other triptans/ergots (within 24 hours).
    • Ditans (5-HT1F Receptor Agonists): New class, binds to 5-HT1F receptors without vasoconstriction.
      • Lasmiditan: PO 50-200 mg. (Can cause CNS depression; driving impairment warning for 8 hours).
    • Gepants (CGRP Receptor Antagonists): New class, orally available CGRP antagonists.
      • Rimegepant: PO 75 mg ODT. (Also approved for prevention).
      • Ubrogepant: PO 50-100 mg.
      • Zavegepant: Nasal spray 10 mg.

  • Stabilization (Early Management Priorities):

    • Anti-emetics: To treat nausea/vomiting and facilitate absorption of oral medications. Can also have intrinsic anti-migraine properties.
      • Metoclopramide: 10-20 mg PO/IV/IM.
      • Prochlorperazine: 5-10 mg PO/IV/IM.
      • Ondansetron: 4-8 mg PO/IV.
    • Combinations: OTC formulations (e.g., Excedrin Migraine: aspirin/acetaminophen/caffeine) are effective for mild-moderate attacks.
    • Adjunctive Therapies:
      • Magnesium: IV magnesium sulfate (1-2 g IV over 15-30 min) may be effective for acute attacks, especially in those with aura or menstrual migraine.
      • Dexamethasone: A single dose of dexamethasone (10-24 mg PO/IV) may be considered to reduce the risk of headache recurrence in the ED, especially for status migrainosus, but not recommended for routine use due to side effects.

  • Emergency (Crisis Management for Status Migrainosus or Severe Attacks):

    • IV Fluids: For dehydration due to prolonged vomiting.
    • IV Anti-emetics:
      • Metoclopramide: 10-20 mg IV (with diphenhydramine 25-50 mg IV to prevent akathisia).
      • Prochlorperazine: 10 mg IV.
    • IV NSAIDs:
      • Ketorolac: 30-60 mg IV/IM.
    • IV Dihydroergotamine (DHE): 0.5-1 mg IV slowly (with anti-emetic like metoclopramide) repeated every 8 hours for up to 3 doses. Potent vasoconstrictor; contraindications similar to triptans.
    • Corticosteroids: Dexamethasone (10-24 mg IV) may be used in the ED to break status migrainosus or prevent recurrence.
    • Opioids and Barbiturates: Generally discouraged due to risk of medication overuse headache, dependence, and lack of migraine-specific action. Reserved for specific contraindications to other agents and as a last resort in hospital settings.

Chronic Management (Preventive Treatment)

Indicated for patients with frequent (≥4 headaches/month), severe, or disabling migraine attacks that significantly impact quality of life, or when acute treatments are ineffective or contraindicated. Goals are to reduce frequency, severity, and duration of attacks, and improve response to acute treatment.

  • Pharmacological: Requires daily, consistent dosing for several months to assess efficacy. Start low, titrate slow.

    • Beta-Blockers: Effective, generally well-tolerated.
      • Propranolol: 20-80 mg BID (up to 240 mg/day).
      • Metoprolol: 25-100 mg BID.
      • Contraindications: Asthma, COPD, heart block, severe bradycardia, uncontrolled heart failure.
    • Anticonvulsants:
      • Topiramate: 25-100 mg/day, titrated slowly. (Can cause paresthesias, cognitive slowing, weight loss, kidney stones, metabolic acidosis).
      • Valproate/Divalproex Sodium: 250-500 mg BID (up to 1500 mg/day). (Can cause weight gain, tremor, hair loss, liver toxicity, pancreatitis, teratogenicity – contraindications in pregnancy).
    • Tricyclic Antidepressants (TCAs): Useful for comorbid depression/anxiety, or sleep disturbance.
      • Amitriptyline: 10-50 mg QHS (low dose for migraine prevention). (Can cause sedation, anticholinergic effects, weight gain).
    • Calcium Channel Blockers: Less evidence than others.
      • Verapamil: 120-240 mg/day (primarily for migraine with aura, cluster headache).
    • CGRP Monoclonal Antibodies (CGRP mAbs): Novel, highly effective class for episodic and chronic migraine. Administered subcutaneously (monthly) or intravenously (quarterly).
      • Erenumab (Aimovig): 70-140 mg SC monthly. (Targets CGRP receptor).
      • Fremanezumab (Ajovy): 225 mg SC monthly or 675 mg SC quarterly. (Targets CGRP ligand).
      • Galcanezumab (Emgality): 120 mg SC monthly (240 mg loading dose). (Targets CGRP ligand).
      • Eptinezumab (Vyepti): 100-300 mg IV quarterly. (Targets CGRP ligand).
      • Side effects: Injection site reactions, constipation (erenumab), hypersensitivity reactions. Generally well-tolerated.
    • OnabotulinumtoxinA (Botox): For chronic migraine only (≥15 headache days/month). Administered via 31 injections across 7 head/neck muscle areas every 12 weeks.
    • Oral CGRP Receptor Antagonists (Gepants):
      • Rimegepant (Nurtec ODT): 75 mg every other day. (Approved for prevention and acute treatment).
      • Atogepant (Qulipta): 10-60 mg PO daily. (Approved for prevention).
    • Other: Candesartan (ACE inhibitor), Lisinopril (ACE inhibitor), Venlafaxine (SNRI).

  • Non-pharmacological: Crucial adjuncts to medication.

    • Lifestyle Modifications:
      • Trigger Avoidance: Identify and avoid individual triggers (food, stress, sleep deprivation).
      • Regular Sleep Schedule: Maintain consistent bedtimes and wake times.
      • Regular Meals and Hydration: Prevent hunger and dehydration.
      • Regular Exercise: Moderate aerobic exercise (e.g., 30 minutes, 3-4 times/week) can reduce frequency and severity.
      • Stress Management: Relaxation techniques (deep breathing, progressive muscle relaxation), yoga, meditation, mindfulness.
    • Behavioral Therapies:
      • Biofeedback: Teaches control over physiological responses (e.g., muscle tension, temperature) to reduce headache frequency.
      • Cognitive Behavioral Therapy (CBT): Helps identify and change unhelpful thoughts and behaviors related to pain and stress.
      • Relaxation Training: Techniques to reduce muscle tension and stress.
    • Nutritional Supplements: Evidence is mixed, but some show promise.
      • Riboflavin (Vitamin B2): 400 mg/day.
      • Magnesium: 400-600 mg/day (oxide, citrate, or glycinate).
      • Coenzyme Q10: 100-300 mg/day.
      • Feverfew: Herbal supplement (standardized extracts).
    • Device-based Therapies:
      • Transcranial Magnetic Stimulation (TMS): Single-pulse TMS device for acute and preventive treatment.
      • Non-invasive Vagus Nerve Stimulation (nVNS): Handheld device placed on the neck.
      • Remote Electrical Neuromodulation (REN): Worn on the arm.
      • External Trigeminal Nerve Stimulation (eTNS): Applied to the forehead.

  • Monitoring:

    • Headache Diary: Essential for tracking frequency, severity, duration, acute medication use, and identifying triggers. Used to assess the efficacy of preventive treatment.
    • Regular Follow-up: Every 1-3 months during preventive treatment initiation/titration, then every 3-6 months.
    • Side Effect Monitoring: For specific medications (e.g., liver/kidney function, electrolytes, weight, mood).
    • Quality of Life Assessment: Using validated questionnaires (e.g., HIT-6, MIDAS).

Treatment Algorithms

  • First-Line (Acute):

    1. Mild to Moderate Attack: OTC analgesics/NSAIDs (e.g., ibuprofen 400-800 mg, naproxen 500-1000 mg, aspirin 900-1000 mg + caffeine/acetaminophen).
    2. Moderate to Severe Attack or Mild Disabling Attack: Triptans (e.g., sumatriptan 50-100 mg PO, zolmitriptan 2.5-5 mg PO). Early use is key.
    3. With Nausea/Vomiting: Add anti-emetic (e.g., metoclopramide 10 mg PO/IV). Use non-oral routes for acute agents (nasal spray triptans, injectables, suppositories).

  • First-Line (Preventive): Consider if ≥4 disabling attacks/month, or ≥8 total headache days/month, or significant disability despite acute treatment.

    1. Initial Choice: Beta-blockers (propranolol, metoprolol) or Topiramate. Amitriptyline is an alternative, especially with sleep disturbance or depression.
    2. Special Considerations:
      • Chronic Migraine: OnabotulinumtoxinA (Botox) is first-line. CGRP mAbs also indicated.
      • Comorbidities: Beta-blockers for hypertension/anxiety; TCAs/SNRIs for depression/anxiety; topiramate for weight loss or epilepsy. Avoid valproate in women of childbearing potential without effective contraception.
      • Recent approvals: Oral CGRP receptor antagonists (rimegepant, atogepant) for prevention.

  • Second-Line (Acute):

    • If triptans are ineffective or contraindicated:
      • Ditans: Lasmiditan.
      • Gepants: Ubrogepant, Rimegepant, Zavegepant.
      • Ergot Alkaloids: Dihydroergotamine (DHE) nasal spray or injection (less common due to side effects and contraindications).
      • Combination Therapies: NSAID + triptan for synergistic effect.
      • Rescue medications: Consider steroids (oral or IM) or IV infusions in emergency settings (e.g., ketorolac, prochlorperazine, DHE).

  • Second-Line (Preventive):

    • If first-line oral agents are ineffective, not tolerated, or contraindicated:
      • CGRP Monoclonal Antibodies: Erenumab, fremanezumab, galcanezumab, eptinezumab. Highly effective and generally well-tolerated.
      • Oral CGRP receptor antagonists (Atogepant): For those not suitable for injectables.
      • Valproate/Divalproex: If other oral agents fail and appropriate for the patient.
      • Other oral agents: Candesartan, venlafaxine.
      • Combination therapy: Combining two prophylactic agents from different classes (e.g., beta-blocker + TCA) may be considered by specialists.

  • Refractory Cases:

    • Medication Overuse Headache (MOH) Management: Crucial step. Withdraw overused acute medications. This often leads to temporary worsening but is essential for long-term improvement.
    • Neuromodulation Devices: Consider non-invasive devices (e.g., Cefaly, gammaCore, Nerivio, sTMS mini) if medications are ineffective or not tolerated.
    • Aggressive Inpatient Treatment: For status migrainosus, consider inpatient protocols with IV DHE, ketorolac, antiemetics, and corticosteroids.
    • Greater Occipital Nerve (GON) Block: Injections of local anesthetic +/- steroid into the GON can provide temporary relief, especially for occipital pain. Can be used as a bridge to other preventive therapies.
    • Referral to Headache Specialist: For complex or refractory cases.
    • Investigational Therapies/Clinical Trials: For truly refractory patients.

Complications

  • Common:

    • Medication Overuse Headache (MOH): Daily or almost daily headache resulting from regular overuse of acute headache medications. This is a major concern in chronic migraine.
    • Chronic Migraine Transformation: Episodic migraine can transform into chronic migraine over time, often driven by factors like increasing attack frequency, medication overuse, and ineffective preventive treatment.
    • Psychiatric Comorbidities: Increased risk of depression, anxiety disorders, and panic disorder. These can worsen migraine and impact treatment outcomes.
    • Sleep Disorders: Insomnia, sleep apnea.

  • Serious:

    • Status Migrainosus: A severe and debilitating migraine attack lasting >72 hours, often requiring hospitalization for aggressive management.
    • Migrainous Infarction: A rare complication where an ischemic stroke occurs during a migraine with aura attack, with persistent neurological deficits and imaging evidence of infarction. More common in younger women, especially those with migraine with aura, smoking, and use of combined oral contraceptives.
    • Persistent Aura without Infarction: Aura symptoms (typically visual) that last for more than one week, with normal neuroimaging.
    • Seizures: Migraine (especially with aura) may increase the risk of seizures, and vice versa. There is a bidirectional relationship.
    • Reversible Cerebral Vasoconstriction Syndrome (RCVS): A condition characterized by sudden severe headaches (thunderclap headache) and segmental vasoconstriction of cerebral arteries, which can sometimes be triggered by triptans or other vasoconstrictors. Migraine patients may be predisposed.

  • Long-term:

    • Increased Cardiovascular Risk: Some studies suggest a modest increased risk of stroke, myocardial infarction, and atrial fibrillation, particularly in women with migraine with aura.
    • Structural Brain Changes: While often asymptomatic, white matter lesions, or "migraine lesions," can be seen on MRI in some patients. Their clinical significance is still debated but generally considered benign.
    • Impaired Quality of Life: Chronic pain and disability can lead to significant impairment in work, social life, and overall well-being.
    • Cognitive Impairment: Some studies suggest subtle cognitive deficits (e.g., attention, processing speed) in chronic migraineurs, particularly during attacks.

Prognosis

  • Factors Affecting Outcome:

    • Frequency and Severity: Higher frequency and severity of attacks are associated with worse prognosis and greater disability.
    • Presence of Aura: Migraine with aura (especially frequent or prolonged aura) may be associated with a slightly higher risk of stroke, though the absolute risk remains low.
    • Medication Overuse Headache: Can significantly worsen prognosis if not addressed.
    • Comorbidities: Psychiatric disorders (depression, anxiety), other chronic pain conditions, obesity, and sleep disorders can negatively impact migraine prognosis and treatment response.
    • Early vs. Late Onset: Childhood migraine may resolve or improve in adulthood for some, but can also persist. New onset migraine in older adults warrants careful workup for secondary causes.
    • Treatment Adherence: Adherence to preventive medications and lifestyle modifications is crucial for improving outcomes.
    • Family History: A strong family history of severe migraine may indicate a more resistant course.
    • Sociodemographic Factors: Lower socioeconomic status and limited access to care may worsen outcomes.

  • Survival: Migraine itself is not a life-threatening condition, and does not directly affect lifespan. However, it can increase the risk of certain cardiovascular events (e.g., stroke), which are rare but can be life-threatening. The main impact is on quality of life and disability.

  • Quality of Life:

    • Significant Impairment: Migraine is a highly disabling condition. Patients often experience significant impairment in daily activities, work or school performance, social interactions, and family life.
    • Reduced Productivity: Frequent attacks lead to absenteeism from work/school (presenteeism and absenteeism).
    • Psychological Burden: Chronic pain and uncertainty of attacks can lead to anxiety, depression, fear of next attack, and feelings of helplessness.
    • Social Isolation: Patients may withdraw from social activities due to fear of triggering attacks or inability to participate during attacks.
    • Functional Outcomes: Measures like the Migraine Disability Assessment Scale (MIDAS) and Headache Impact Test (HIT-6) quantify the impact on quality of life and functional ability. Significant improvement in these scores is a key treatment goal.
    • Remission: While migraine is a chronic condition, some individuals experience periods of remission, especially after menopause for women.

Prevention

Prevention aims to reduce the frequency, severity, and duration of migraine attacks, thereby improving quality of life and reducing the need for acute medications.

  • Primary Prevention: Preventing the initial occurrence of migraine (less applicable as it's often genetically predisposed, but refers to general health promotion).

    • Healthy Lifestyle: Promoting a generally healthy lifestyle from childhood may indirectly reduce the likelihood or severity of migraine. This includes:
      • Regular exercise (moderate intensity).
      • Balanced diet, avoiding skipping meals.
      • Adequate hydration.
      • Consistent sleep schedule.
      • Effective stress management techniques.

  • Secondary Prevention: Early detection and intervention to reduce the frequency and severity of attacks in diagnosed migraineurs, or to prevent transformation to chronic migraine.

    • Trigger Identification and Avoidance: Maintain a headache diary to identify individual triggers (foods, stress, sleep patterns, environmental factors, hormonal changes). Once identified, patients can try to avoid or manage these triggers.
    • Pharmacological Prophylaxis: Initiate preventive medications when:
      • Migraine attacks are frequent (e.g., ≥4 days per month).
      • Attacks are severe and significantly disabling, despite acute treatment.
      • Acute medications are contraindicated, ineffective, or cause intolerable side effects.
      • There is a risk of medication overuse headache.
      • Patient preference for prevention over frequent acute treatment.
      • Prophylactic agents, as detailed in the "Chronic Management - Pharmacological" section (e.g., beta-blockers, topiramate, CGRP mAbs, Botox).
    • Non-pharmacological Approaches: Behavioral therapies (biofeedback, CBT, relaxation training), nutritional supplements (riboflavin, magnesium, CoQ10), and device-based therapies (e.g., Cefaly, nVNS) can significantly contribute to prevention.
    • Management of Comorbidities: Addressing co-existing conditions like depression, anxiety, sleep disorders, and obesity can improve migraine control.

  • Tertiary Prevention: Preventing complications of migraine, such as chronic migraine transformation or medication overuse headache.

    • Limiting Acute Medication Use: Educate patients on the risk of medication overuse headache. Limit triptan use to 9 days/month, NSAIDs to 15 days/month, and combination analgesics/opioids to 9 days/month.
    • Early Intervention for Chronic Migraine: Aggressive preventive strategies (e.g., Botox, CGRP mAbs) and withdrawal of overused acute medications are crucial once chronic migraine is established.
    • Managing Migraine in Special Populations: Tailoring prevention strategies for children, pregnant women, or those with specific comorbidities (see "Special Populations" section).
    • Patient Education: Empower patients with knowledge about their condition, management strategies, and the importance of adherence to prevent long-term complications.

Special Populations

Migraine management needs to be tailored for specific patient groups due to physiological differences, unique risks, or drug interactions.

  • Pediatric:

    • Presentation: Often shorter duration (2-72 hours), more commonly bilateral, and may have more prominent gastrointestinal symptoms (abdominal pain, vomiting). Aura can be more varied. Cyclic vomiting syndrome, benign paroxysmal vertigo of childhood, and abdominal migraine are migraine variants in children.
    • Diagnosis: ICHD-3 criteria are adapted for children (e.g., shorter duration).
    • Acute Treatment:
      • First-line: NSAIDs (ibuprofen 10 mg/kg, naproxen 5-7 mg/kg) and acetaminophen.
      • Triptans: Sumatriptan nasal spray (5-10 mg for >12 years), Zolmitriptan nasal spray (5 mg for >12 years), Rizatriptan ODT (5-10 mg for >6 years, weight-based dosing for younger). Oral triptans generally approved for adolescents >12 years.
      • Anti-emetics: Ondansetron.
    • Preventive Treatment:
      • First-line: Topiramate (titrate slowly, monitor for cognitive side effects), Amitriptyline (low dose). Propranolol.
      • Non-pharmacological: Crucial emphasize sleep hygiene, hydration, regular meals, stress reduction, and biofeedback/CBT. Supplements like Riboflavin and CoQ10 are often considered due to good safety profile.

  • Geriatric:

    • Presentation: New onset migraine after age 50 is uncommon and warrants thorough investigation for secondary causes (e.g., giant cell arteritis, structural lesions, TIA). Migraine with aura may become more prominent or new-onset in older age (acephalgic migraine). Attack frequency and severity may decrease after age 60.
    • Acute Treatment:
      • NSAIDs: Use with caution due to increased risk of GI bleeding, renal impairment, and cardiovascular events.
      • Triptans: Contraindicated in patients with significant cardiovascular risk factors (ischemic heart disease, uncontrolled hypertension, history of stroke/TIA) more common in elderly. Lasmiditan or gepants may be safer alternatives if no contraindications.
    • Preventive Treatment:
      • Beta-blockers: Use with caution due to potential for bradycardia, hypotension, and exacerbation of heart failure or asthma.
      • Topiramate: Monitor for cognitive side effects, glaucoma, and weight loss.
      • CGRP Monoclonal Antibodies: Generally well-tolerated and can be a good option given fewer drug-drug interactions and systemic side effects compared to older agents.
      • Polypharmacy: Careful review of all medications to avoid drug interactions.

  • Pregnancy and Lactation:

    • General: Migraine often improves during pregnancy (especially 2nd/3rd trimester), but can worsen postpartum.
    • Acute Treatment:
      • First-line: Acetaminophen.
      • NSAIDs: Avoid in 3rd trimester due to risk of premature ductus arteriosus closure and oligohydramnios. Use caution in 1st and 2nd trimesters.
      • Triptans: Sumatriptan has the most safety data (Category C/B3), but generally avoided if possible. Use only if benefits outweigh risks.
      • Opioids: Generally avoided due to risk of neonatal withdrawal syndrome.
      • Anti-emetics: Ondansetron, metoclopramide, promethazine are relatively safe.
      • Non-pharmacological: Ice packs, rest, biofeedback.
    • Preventive Treatment: Generally avoided during pregnancy.
      • Beta-blockers: Propranolol may be used, but monitor for fetal growth restriction/bradycardia.
      • Valproate and Topiramate: Absolute contraindication due to high risk of neural tube defects and oral clefts, respectively.
      • CGRP mAbs: Limited data, generally avoided.
      • Botox: Limited data, generally avoided.
      • Lactation: Most triptans have low transfer into breast milk. Acetaminophen, ibuprofen, sumatriptan are generally considered compatible with breastfeeding with caution. Always consult a lactation specialist or review up-to-date guidelines (e.g., LactMed).

  • Comorbidities:

    • Depression/Anxiety: Very common. Choose preventive agents that also treat these conditions (e.g., amitriptyline, venlafaxine, CGRP mAbs). CBT is highly recommended.
    • Obesity: Associated with increased migraine frequency and severity. Weight loss can improve migraine outcomes.
    • Cardiovascular Disease: Caution with triptans and ergots. Use CGRP mAbs, topiramate, or non-pharmacological methods. Assess stroke risk in migraine with aura.
    • Epilepsy: Topiramate or valproate can treat both conditions.
    • Asthma/COPD: Avoid beta-blockers.
    • Hypertension: Beta-blockers or candesartan are good choices.
    • Insomnia: Amitriptyline can be beneficial due to sedative effects.

Clinical Pearls

  • Diagnostic:

    • The diagnosis is clinical: Rely heavily on patient history. No specific test confirms migraine.
    • SNOOP10: Always consider red flags to rule out secondary headaches. If a patient describes "the worst headache of my life," assume subarachnoid hemorrhage until proven otherwise.
    • Aura types: Remember aura can be visual, sensory, speech/language, or even motor. Atypical aura warrants imaging.
    • Migraine with aura and stroke risk: While generally low, consider stroke risk factors (e.g., smoking, oral contraceptives) in women with migraine with aura.
    • Medication Overuse Headache (MOH): Be vigilant for MOH in patients with chronic daily headache and frequent acute medication use. This is a common and often overlooked cause of treatment failure.

  • Treatment:

    • Early Intervention is Key: Acute medications (especially triptans) work best when taken at the first sign of headache pain, not waiting for it to become severe.
    • Set Expectations: Preventive medications take weeks to months to show effect and may only reduce frequency/severity by 50%. Complete remission is rare.
    • Start Low, Go Slow: When initiating preventive medications, start with low doses and titrate gradually to minimize side effects and improve tolerability.
    • Combination Therapy: For acute attacks, combination products (e.g., NSAID + triptan) or adding an anti-emetic can be more effective.
    • Non-Pharmacological Strategies are NOT Optional: Lifestyle modifications, stress management, and behavioral therapies are foundational to successful migraine management.
    • CGRP mAbs Revolution: These newer agents are well-tolerated and highly effective, offering a significant advance, especially for chronic and refractory migraine.

  • Pitfalls:

    • Under-treating Migraine: Not providing adequate acute or preventive treatment, leading to increased disability and risk of chronic migraine.
    • Over-reliance on Opioids/Barbiturates: These should generally be avoided for migraine due to lack of specific efficacy, risk of MOH, and dependence.
    • Ignoring Comorbidities: Failing to address co-existing conditions like depression, anxiety, or sleep disorders, which can exacerbate migraine.
    • Inadequate Medication Adherence: Patients stop preventive medications too soon due to side effects or lack of immediate effect. Emphasize consistency and patience.
    • Not Addressing MOH: Continuing to prescribe acute medications frequently without addressing the underlying MOH will perpetuate the headache cycle. Gradual withdrawal of overused medications is essential.
    • Skipping Imaging when Indicated: Missing secondary causes of headache by not imaging when red flags are present.
    • Not Using Headache Diaries: Without a diary, it's difficult to accurately assess attack frequency, severity, triggers, and treatment efficacy.

Recent Updates

  • Guidelines:

    • American Academy of Neurology (AAN) and American Headache Society (AHS) Guidelines: Continuously updated to incorporate new evidence, particularly regarding CGRP monoclonal antibodies, gepants, and ditans for both acute and preventive treatment.
    • National Institute for Health and Care Excellence (NICE) Guidelines (UK): Provide comprehensive recommendations for diagnosis and management, including criteria for initiating different treatment classes.
    • European Headache Federation (EHF) Guidelines: Offer consensus statements and recommendations, often aligning with AAN/AHS and NICE but with regional considerations.

  • Evidence:

    • CGRP Pathway Targeting: Extensive evidence has emerged supporting the efficacy and safety of CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) for migraine prevention in both episodic and chronic migraine. They have shown superior tolerability profiles compared to traditional oral preventives.
    • Oral CGRP Receptor Antagonists (Gepants): Rimegepant, ubrogepant, zavegepant are now approved for acute treatment, providing non-triptan options. Atogepant and rimegepant are also approved for preventive treatment, offering oral daily/every other day options that target the CGRP pathway.
    • Ditans: Lasmiditan, a selective 5-HT1F agonist, offers an acute treatment option without vasoconstrictive effects, making it a potential alternative for patients with cardiovascular contraindications to triptans, although with CNS side effects like dizziness and sedation.
    • Device-Based Therapies: Growing evidence for non-invasive neuromodulation devices (e.g., single-pulse transcranial magnetic stimulation, external trigeminal nerve stimulation, remote electrical neuromodulation, non-invasive vagus nerve stimulation) as adjunctive or standalone treatments for acute and/or preventive migraine.

  • Controversies:

    • Long-term Safety of CGRP Pathway Modulators: While generally well-tolerated, long-term cardiovascular safety (especially in patients with pre-existing conditions) and potential effects on pregnancy are still under active investigation as more real-world data accumulates.
    • Role of Opioids in Migraine: The debate continues regarding the appropriate place (if any) for opioids in migraine management, with strong recommendations against their routine use due to efficacy, safety, and addiction concerns, balanced against the need for rescue therapies in specific severe cases.
    • Optimal Timing for Preventive Therapy Initiation: While general guidelines exist (e.g., ≥4 attacks/month), the precise threshold and optimal timing for initiating preventive therapy in patients with less frequent but highly disabling attacks remain an area of clinical judgment.
    • Managing Medication Overuse Headache: While withdrawal is the cornerstone, the optimal approach to facilitate withdrawal and maintain long-term abstinence, especially in combination with new preventive therapies, is complex.

Key References

  • Guidelines:

    • Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018 Jan;38(1):1-211.
    • American Headache Society (AHS) and American Academy of Neurology (AAN) Guidelines: Regularly updated position statements and practice guidelines on the pharmacological treatment of migraine. Refer to their official websites.
    • National Institute for Health and Care Excellence (NICE) Guidelines: Headaches in over 12s: diagnosis and management. (CG150, updated 2021).
    • European Headache Federation (EHF) Guidelines on the treatment of migraine.

  • Studies:

    • Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Sep 25;79(12):1338-45. (Though newer agents like CGRP mAbs are not included, it's a foundational guideline).
    • Ashina M, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020 Jan;40(1):24-37.
    • Dodick DW, et al. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Erenumab in Episodic Migraine. Cephalalgia. 2018 Oct;38(11):1839-1849.
    • Reuter U, et al. Efficacy and safety of fremanezumab in patients with chronic migraine: A randomized, controlled trial. Neurology. 2018 May 1;90(18):e1704-e1713.
    • Biondi DM. A review of raniregant in migraine management. Expert Opin Pharmacother. 2021 Aug;22(12):1701-1710.
    • Goadsby PJ, et al. Oral rimegepant for acute migraine. N Engl J Med. 2020 Feb 20;382(7):658-660.
    • Croop R, et al. Oral atogepant for the prophylaxis of episodic migraine in adults. N Engl J Med. 2021 Aug 19;385(8):695-705.

  • Reviews:

    • Charles A. The pathophysiology of migraine: an update. Curr Opin Neurol. 2018 Jun;31(3):271-275.
    • Lipton RB, et al. Diagnosis and management of migraine. Am Fam Physician. 2013 Dec 1;88(11):762-790.
    • Dodick DW. Migraine. Lancet. 2018 Nov 24;392(10161):2516-2531.

Dr. Vivek's AI | For Educational Purposes Only